Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology ...

The safety results from the EoE KIDS study were consistent with the known safety profile of Dupixent in adolescents and ...

A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the European Commission (EC) to treat eosinophilic ...

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi have announced that the European Commission has granted approval for Dupixent ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Traditionally, this finding has been attributed solely to peptic injury, but with the advent of EoE, a second potential etiologic entity is recognized. Some patients may exhibit clinical features ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Explore the potential of Celldex's Barzolvolimab in Phase 3 for CSU, with strong efficacy but safety concerns, promising ...

Open Until Filled. AA/EOE. Do not apply to KUOW directly. You are invigorated by a busy day and think a quiet one is a snooze. You juggle paper on your desk, emails in your inbox, and visitors to ...

Eupraxia Pharma reports positive data from RESOLVE phase 1b/2a trial of EP-104GI for treatment of eosinophilic esophagitis: Victoria, British Columbia Thursday, November 14, 2024, ...